Literature DB >> 8002061

Morning steroid profile in children with congenital adrenal hyperplasia under different hydrocortisone schedules.

I N Silva1, D F Oliveira-Júnior, C J Simal, M B Viana, A J Chagas.   

Abstract

We studied 13 children with 21-hydroxyalse deficiency to explore the immediate potential suppressive effect of hydrocortisone dose schedule on the adrenal cortex. They were given 20 mg/m2 daily in a controlled trial. After random administration of a greater dose in the morning (7 patients) or at night (6 patients), we measured plasma levels of 17-hydroxyprogesterone, testosterone, and androstenedione at times-24, 0, 2, 4, and 6h. Considerable fluctuation of the steroid levels, unrelated to the drug intake, was observed. There was no statistically significant differences between the "morning dose" and "night dose" groups for any steroid. We conclude that; (i) the greater night dose did not avoid the 17-hydroxyprogesterone morning peaks, and (ii) the variation in plasma steroid levels is so marked that a single morning sample is unreliable to reflect the degree of adrenal suppression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8002061     DOI: 10.1007/BF02751885

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  7 in total

1.  The suppression of androgen secretion by cortisone in a case of congenital adrenal hyperplasia.

Authors:  L WILKINS; R A LEWIS; R KLEIN; E ROSEMBERG
Journal:  Bull Johns Hopkins Hosp       Date:  1950-04

2.  Response to treatment of congenital adrenal hyperplasia in infancy.

Authors:  M C Young; I A Hughes
Journal:  Arch Dis Child       Date:  1990-04       Impact factor: 3.791

3.  The effect of treatment of final height in classical congenital adrenal hyperplasia (CAH).

Authors:  J DiMartino-Nardi; E Stoner; A O'Connell; M I New
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1986

4.  Serum 17-alpha-hydroxyprogesterone, progesterone, estradiol, and testosterone in the diagnosis and management of congenital adrenal hyperplasia.

Authors:  B M Lippe; S H LaFranchi; N Lavin; A Parlow; J Coyotupa; S A Kaplan
Journal:  J Pediatr       Date:  1974-12       Impact factor: 4.406

5.  Current approaches to the treatment of congenital adrenal hyperplasia.

Authors:  J S Winter
Journal:  J Pediatr       Date:  1980-07       Impact factor: 4.406

6.  The application of a serum 17OH-progesterone radioimmunoassay to the diagnosis and management of congenital adrenal hyperplasia.

Authors:  I A Hughes; J S Winter
Journal:  J Pediatr       Date:  1976-05       Impact factor: 4.406

7.  Circadian patterns of plasma cortisol, 17-hydroxyprogesterone, and testosterone in congenital adrenal hyperplasia.

Authors:  H Frisch; K Parth; E Schober; W Swoboda
Journal:  Arch Dis Child       Date:  1981-03       Impact factor: 3.791

  7 in total
  3 in total

1.  Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia.

Authors:  I N Silva; C E Kater; C F Cunha; M B Viana
Journal:  Arch Dis Child       Date:  1997-09       Impact factor: 3.791

2.  Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises.

Authors:  Karen J Loechner; James T McLaughlin; Ali S Calikoglu
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-24

3.  Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia.

Authors:  Sze May Ng; Karolina M Stepien; Ashma Krishan
Journal:  Cochrane Database Syst Rev       Date:  2020-03-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.